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COMMERCIAL INFLUENCE IN HEALTH: FROM TRANSPARENCY TO
INDEPENDENCE
Mandatory disclosure of financial interests of journals and editors
Medical journals must be as transparent as they require their authors to be, argue Rafael Dal-Ré
and colleagues
Rafael Dal-Ré, 1 Lex M Bouter, 2 David Moher, 3 Ana Marušić4
Transparency of interests (or potential conflicting
interests) by editors and authors allows readers to
judgewhether these are relevant for the interpretation
of the article. Authors who fail to disclose conflicts
of interest (COIs) may face consequences. For
example, as of April 2020 conflict of interest was
listed in the reasons for retraction for 165 articles in
the Retraction Watch database1 and was the sole
reason for the retraction of 19 (11%) articles.1 Failure
to disclose COIs has led to job loss in some cases,2
and the International Committee of Medical Journal
Editors (ICMJE) considers non-disclosure as research
misconduct.3
Journal editors, however, do not face such
recriminations because readers do not know about
their potential COIs as they are rarely available in the
public domain. This lack of transparency jeopardises
journals and professional organisations credibility
and trust, especially as the publication business is
highly profitable.4 5 We believe that journal editors,
their professional organisations, and commercial
publishers should not only have policies for the
public disclosure of potential COIs of editorial team
members but fully implement them. To be fully
transparent, journals should also disclose their
financial interests each year.
Transparency of editor’s financial interests
The ICMJE—whose current 12 member journals
include influential general and internal medicine
journals such as New England Journal of Medicine,
Lancet, JAMA, The BMJ, and Annals of Internal
Medicine—produces guidance on the conduct,
reporting, editing, andpublicationof scholarlywork.3
Its recommendations on author declarations are
followedby thousands ofmedical journals and those
in other research fields.3 However, medical journals
donot performwell in following the ICMJE standards
for disclosing editors’ COIs.
In a cross-sectional analysis of a random sample of
350 medical journals listed as following ICMJE
recommendations in 2018, less than 1% of the
journals disclosed editors’ individual COIs, whereas
82% required the disclosure of authors’ COIs.6
Another studyofwebsites of 130 top specialtymedical
journals in 2018 showed that only 45% endorsed the
ICMJE recommendations and 12% disclosed
individual editors’ COIs whereas 99% required
authors to disclose their COIs (table 1).7 In this study,
69% of the journals were linked to a professional
organisation (society, association, or college) or a
public institution7; the professional community and
the public expect such institutions to be transparent
about their work, including journal publication.
Table 1 | Journal policy on disclosure of authors’ and individual editors’ financial COIs
No (%) providing editors’ COIsNo (%) requesting author
disclosure
NoType of journal
16 (12)129 (99)130*Highly influential7
2 (0.6)287 (82)350†ICMJE followers6
2 (17)12 (100)12ICMJE members8
* Top five journals in 26 journal citations report categories.
† Random sample of all journals listed as followers of the ICMJE recommendations.
Among the ICMJE member journals, only The BMJ
discloses individual editors’ COIs on the journal
website, though the Annals of Internal Medicine
discloses editorial COIs for certain types of online
articles.8 Most do not seem to follow their own
recommendations for declaring editors’ COIs (table
1).8 This lack of transparency from the journals that
created and regularly update the ICMJE
recommendations is worrying, especially in view of
the recent statements from the New England Journal
of Medicine that their editors should have no
“financial relationships with any biomedical
companies” and from the Lancet that the journal
complies “with additional company [Elsevier] COI
policies and procedures.”9 It is not clear why these
large and influentialmedical journals donot publicly
disclose whether their editors should have no
financial COIs or, if this is not a condition for the
editorial team, why they do not publish the details
of any such COIs.
1the bmj | BMJ 2020;370:m2872 | doi: 10.1136/bmj.m2872
ANALYSIS
1 Epidemiology Unit, Health Research
Institute-Fundación Jiménez Díaz
University Hospital, Universidad
Autónoma de Madrid, Madrid, Spain
2 Department of Epidemiology and
Data Science, Amsterdam University
Medical Centers, and Department of
Philosophy, Vrije Universiteit
Amsterdam, Netherlands
3 Centre of Journalology, Clinical
Epidemiology Program, Ottawa
Hospital Research Institute; School
of Epidemiology and Public Health,
University of Ottawa, Ottawa, Canada
4 Department of Research in
Biomedicine and Health, University
of Split School of Medicine, Split,
Croatia
Correspondence to: R Dal-Ré
rafael.dalre@quironsalud.es
Cite this as: BMJ 2020;370:m2872
http://dx.doi.org/10.1136/bmj.m2872
Published: 23 September 2020













J: first published as 10.1136/bm
j.m






The World Health Organization has a critical role in clinical trials
transparency through the International Clinical Trials Platform and
by sponsoring trial registries in developing countries, yet its flagship
journal (Bulletin of the World Health Organization) does not disclose
its editors’ COIs. This is despite it being an ICMJE member.8
Similarly, prominent journals linked to public health organisations
like Eurosurveillance from the European Centre for Disease
Prevention and Control (ECDC), and Emerging Infectious Diseases
and Morbidity Mortality Weekly Report from the US Centers for
Disease Control and Prevention, do not disclose their editors’ COIs.7
Whereas payments to some journal editors have been reported in
the US because of the existence of a national database on industry
payments to physicians,10 11 there are few reports on industry
payments to healthcare professionals in other countries12 -15 and
none regarding payments to journal editors. The lack of
transparency for editors’ COIs does not seem to diminish journals’
prestige, as authors keep submitting manuscripts to journals that
do not follow disclosure standards. This is troubling.
Others involved in editorial process
ICMJE recommendations also require peer reviewers to disclose
COIs to editors and recuse themselves from the review process if
needed.3 However, only three of the 12 ICMJE member journals had
a publicly available policy on reviewers’ disclosure of COIs.8 Since
reviewers’ identities are often kept confidential, the ICMJE
recommendations do not require public disclosure of reviewers’
COIs.3 However, a small but increasing number of journals are
publishing both the names of the reviewers and their comments
together with the article. In this open peer review model16 journals
should disclose reviewers’ COIs. Some journals already do this—for
example, all the BMC medical journals17—showing that disclosure
is feasible.18
Transparency of journals’ financial interests
Scientific journals, as business enterprises, also have financial
interests such as revenues from article reprints sales,
advertisements, and commercial sponsorships. Again, these are
rarely disclosed. There are no policies for this type of declaration,
as judged by the publishing ethics polices of major medical
publishers.19 -21
In 2016, more than $630m (£470m; €530m) was spent on print
advertisements in medical journals.22 Drug advertisements in
medical journals have been a concern for some time, since they
may appear to influence editorial decisions.23 Income from reprints,
particularly of industry funded trials, is considered to be a financial
conflict of interest.24 -26 In two studies of journal revenues, three
journals owned by US professional organisations (New England
Journal of Medicine, JAMA, and Annals of Internal Medicine) refused
to provide figures of their reprints orders, in contrast to The BMJ
(also owned by a professional organisation) and the commercially
owned Lancet.24 25 These studies were conducted almost 10 years
ago, but we were still unable to find this information on these
journals’ websites, even though societal pressure for transparency
has significantly increased.
Journals that generate considerable revenues from reprint sales are
usually influential journals.24 25 Furthermore, higher numbers of
reprints may result in more citations, which in turn boosts the
journal’s impact factor and prompts trial sponsors to request more
reprints of newlypublishedarticles. Industry funded trials published
in highly influential journals are more often cited than trials with
non-industry funding.25 27 The use of reprints as a marketing tool
likely affected this finding, although the fact that industry trials
more often report positive outcomes28 could also explain why they
are more cited.29 30
It is very unusual for journals to report their annual revenues, but
BMJ started to report this information for its journals in 2017.31 Even
if it is understandable that commercial journal owners might want
to keep their revenues confidential, it is difficult to justify the lack
of transparency about revenues by journals belonging to
professional or public organisations.
Opening up
Medical journals should start disclosing COIs for individual editors,
and commercial revenues from commercial sources should be
disclosed each year. Journal editors should also be responsible for
ensuring that everyone involved in the editorial decisions publicly
discloses their COIs.
Although there are proposals to establish nationally funded open
access registries to allow complete disclosure of COIs,32 we do not
believe that registries alone can provide transparency in research
publishing. Disclosure of individual editors’ COIs belongs on
journals’ websites or, in mega-journals that have many editors, in
the articles, as these are where most readers would most likely look
for this type of information.
We believe that authors’ and readers’ trust in journals will increase
if journals show themselves to be as transparent about editorial and
journal COIs as they require their authors to be. We call for all
medical journals to disclose their editors’ COIs on the journals’
website and keep this information updated. Another possibility is
to publish the information on COIs regularly in their journals so
that such declarations become a part of the published record and
indexed in bibliographical databases, just as it is for the journal
authors when they publish their articles.
The approach may need to differ for large editorial teams, such as
in mega-journals (eg, BMJ Open, Plos One, Scientific Reports) that
have hundreds of editors. The name of the editor and their COIs
could be reported at the place in the article where authors’ COIs are
disclosed. Another option is to link the editor’s name in the
published article to the journal site where all editors’ COIs are
reported and updated.
We suggest that journals belonging to the same
organisation—whether a professional organisation (eg, American
Heart Association, British Medical Association) or a group of related
journals (eg, Lancet, Nature Reviews)—should have a uniform
approach todisclosure of editors’COIs. Currently, the fewpublishers
that disclose editors’ COIs, implement the policy inconsistently. For
example, within BMJ, the flagship journal (The BMJ) discloses the
COIs of all editorial team members, but other BMJ journals disclose
conflicts for one or a few members of their editorial teams.7
Consistency across journals in the same group would increase the
trust of the professional andgeneral public in the transparency and
consistency of publishers’ policies and work.
Transparency is not enough
Transparency about potential COIs is a solution to a rather simple
problem compared with judging their relevance and how to act on
them. Firstly, there is no consensus on when a financial conflict of
interest is serious enough to be disclosed: how high should the
financial stakes be, howclose to the topic of the article, howdistant
in the past, or how near in terms of the relationship (spouse, family
member, close friend, institutional colleague, collaborator in earlier
projects, etc). Secondly, it is also difficult to define and measure
non-financial conflicts. Thirdly, decisions need to be made about
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when a conflict of interest is so large that being transparent is
insufficient and any involvement should be avoided. For example,
if a behavioural therapy is designed by a psychotherapist who also
wrote ahandbookon it, trains new therapists to apply it in practice,
andhas a substantial income from these,webelieve that this person
should not take part in efficacy studies of that behavioural therapy,
or reviewing such studies, or making editorial decisions on them.
Finally, for conflicts where transparency is enough there remains
the almost unanswerable question of how to weigh them: should
we downgrade only the level of evidence or also the strength of the
reported effects?
Key messages
• Disclosure of potential conflicts of interest by authors and editors is
best practice and recommended by the International Committee of
Medical Journal Editors (ICMJE)
• Most journals following ICMJE recommendations require authors to
provide a declaration of interests
• Very few journals, however, disclose individual editors’ COIs
• Editors need to declare their own potential COIs as well as journal
revenues since these might be considered to affect publication
decisions
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